Image via Wikipedia
Health Counselor Board, Javier Alvarez Guisasola, launched on Wednesday a clinical trial coordinated by Professor Margarita Calonge, IOBA’s on cell therapy applied to treat corneal blindness.
This study was coordinated by the IOBA and IBGM to demonstrate the long-term effectiveness of the epithelial stem cell transplantation of the cornea, previously cultivated to restore corneal blindness. Stem cells come from a healthy eye of the patient or family support.
A novel therapy in the early stages of development at Virginia Commonwealth University Massey Cancer Center shows promise in providing lasting protection against the progression of multiple myeloma following a stem cell transplant by making the cancer cells easier targets for the immune system.
Outlined in the British Journal of Hematology, the Phase II clinical trial was led by Amir Toor, M.D., hematologist-oncologist in the Bone Marrow Transplant Program and research member of the Developmental Therapeutics program at VCU Massey Cancer Center. The multi-phased therapy first treats patients with a combination of the drugs azacitidine and lenalidomide. Azacitidine
Image via Wikipedia
Stem cell therapy holds promise for the treatment of almost all human diseases, from spinal cord injuries to damage caused by heart attacks. Stem cells are the cells in our body that have the potential to “grow up” to be any type of cell in the body. But organs are more than just collections of cells. They’re highly organized collections of a multitude of cells.
All treatments with stems cells are still experimental, and therefore the risks of this treatment are not completely understood. Clinical trials are monitored in the United States by academic and government agencies to
Emory University researchers have received approval from the Food and Drug Administration (FDA) to advance to the next phase of a landmark trial to treat patients with Amyotrophic Lateral Sclerosis (ALS) using human neural stem cells.
The Phase I trial, currently underway exclusively at Emory University, is designed to assess the safety of implanting neural stem cells into the spinal cord in up to 18 people with ALS and began in January 2010. The first 12 patients received neural stem cell transplants in the lumbar, or lower, region of the spinal cord. After reviewing safety data from these patients, the
Stem cells from umbilical cords are increasingly being stored in private banks for autologous use. “Newsweek” added to the debate writing about Dallas Hextell, who at the age of 8 months was diagnosed with cerebral paralysis, a condition normally caused by serious neural damage due to oxygen deprivation in the uterus or at birth. His parents consulted various neurologists, but the possibility of a recovery was virtually non-existant.
About 9 months later, when given the opportunity to participate in a Duke University clinical study on autologous stem cell transplants (stem cells that are stored for later use by